And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC

J Thorac Oncol. 2022 Oct;17(10):1144-1154. doi: 10.1016/j.jtho.2022.08.016.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Acrylamides
  • Asia
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • ErbB Receptors / genetics
  • Humans
  • Indoles
  • Lung Neoplasms* / drug therapy
  • Morpholines
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles
  • Pyrimidines

Substances

  • Acrylamides
  • Indoles
  • Morpholines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • lazertinib
  • EGFR protein, human
  • ErbB Receptors
  • aumolertinib